ROCHE INVIRASE CLEARS FDA IN 97 DAYS AS FIRST APPROVED PROTEASE INHIBITOR: NEW FORMULATION IN STUDY; INTERNATIONAL CONFIMATORY TRIAL SIZE, POWER INCREASED
Executive Summary
Hoffmann-La Roche's Invirase (saquinavir) will be the first protease inhibitor on the market following its approval 97 days after the NDA was received by FDA.
You may also be interested in...
Roche Fuzeon Approval Presents Challenges Of Reimbursement, Supply
AIDS Drug Assistance Program coverage of Roche's antiretroviral Fuzeon could hinge upon the agent's role as either replacement or add-on therapy
Roche Fuzeon Approval Presents Challenges Of Reimbursement, Supply
AIDS Drug Assistance Program coverage of Roche's antiretroviral Fuzeon could hinge upon the agent's role as either replacement or add-on therapy
Roche Fuzeon 2003 Production: 15,000-Patient Supply Plus 6-Month Cushion
Roche/Trimeris' 2003 production cap for Fuzeon includes doses for 12,000 to 15,000 patients, in addition to a six-month "safety supply," the companies said during a Dec. 18 analyst call